United States, 2025
+5%since 2024
Source: World Bank
USA · Country · 54 publishers
United States statistics
2,484 verified figures for United States across 30 industries and 573 measures, 1960–2035, from 54 publishers.
Inflation, consumer prices (annual %)
2.95%United States, 2024
−1.2 ppsince 2023
Source: World Bank
Mobile-cellular subscriptions per 100 inhabitants
113.2 per 100 inhabitantsUnited States, 2024
+0.7%since 2023
Source: ITU
DTP3 immunization coverage among 1-year-olds (%)
94%United States, 2025 Estimate
0 ppsince 2024
Source: WHO
Key findings
Drawn from every industry that publishes a figure for United States.
- Internet advertising revenue in the United States was 294.6 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Digital video advertising revenue in the United States was 78 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Semiconductor sales by U.S.-headquartered companies were 425 billion USD in 2025 (SIA). SIA ↗ T2 Official
- Commerce media advertising revenue in the United States was 63.4 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Display advertising revenue in the United States was 81.6 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Podcast advertising revenue in the United States was 2.9 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Programmatic advertising revenue in the United States was 162.4 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Search advertising revenue in the United States was 114.2 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Social media advertising revenue in the United States was 117.7 billion USD in 2025 (IAB). IAB ↗ T2 Official
- Halloween retail spending in the United States was 13.1 billion USD in 2025 (NRF). NRF ↗ T2 Official
United States country profile
Latest verified figure for United States on each panel indicator, with world and continental rank. Ranks compare countries on one reference year per indicator: the most recent year in which at least half of the countries that have ever reported have a figure. Higher values rank first; ties share a rank. Forecasts and future periods are excluded. The value shown is the latest figure, which may be a later year than the rank. See the methodology.
United States statistics by topic
Topic pages for United States. Country rankings it appears in are listed below the tiles.
- Retail · 432 records16.4%E-commerce sales in United States
- Economy · 167 records30,769,700,000,000USDGDP in United States
- Electricity and Gas Utilities · 92 records25.6%Electricity generation in United States
- Pharmaceuticals · 70 records128Clinical trial starts in United States
- Electricity and Gas Utilities · 35 records4,904.1 milliontonnesPower sector CO2 emissions in United States
- Telecommunications · 35 records113.2per 100 inhabitantsMobile subscriptions in United States
- Retail · 30 records6%Retail sales in United States
- Retail · 29 records2.3 millionTEUContainerized retail imports in United States
- Electricity and Gas Utilities · 27 records384.4gCO2e/kWhCarbon intensity of electricity in United States
- Telecommunications · 25 records94.7%Internet users in United States
- Software and IT Services · 22 records23.8%Business technology adoption in United States
- Airlines and Air Transport · 22 records87.5 millionAirline passenger enplanements in United States
- Software and IT Services · 19 records181,800ICT employment in United States
- Construction · 19 records2,157.6 billionUSDConstruction spending in United States
- Electricity and Gas Utilities · 18 records52GWPower generation capacity in United States
- Construction · 16 records43.9USDConstruction hourly earnings in United States
- Pharmaceuticals · 15 records50New drug approvals in United States
- Oil and Gas · 15 records5.58USD/gallonGasoline and diesel prices in United States
- Software and IT Services · 13 records105,850USDTech worker wages in United States
- Electricity and Gas Utilities · 11 records6.9gigawattsPower capacity additions in United States
- Steel and Basic Metals · 10 records7.3 millionmillion tonnesCrude steel production in United States
- Pharmaceuticals · 10 records4 billionUSDMedicine spending in United States
- Steel and Basic Metals · 10 records1,561,961net tonsSteel imports in United States
- Oil and Gas · 10 records3.53USD per million BtuNatural gas spot price in United States
- Banking · 10 records90.1 billionUSDBank net income in United States
- Oil and Gas · 10 records121.3 billioncubic feet per dayNatural gas production in United States
- Steel and Basic Metals · 10 records8,219,540net tonsSteel shipments in United States
- Electricity and Gas Utilities · 8 records17.3cents per kilowatthourElectricity price in United States
- Pharmaceuticals · 8 records125,986 millionUSDPharmaceutical R&D investment in United States
- Banking · 6 records1.8%Bank loans in United States
- Oil and Gas · 6 records84USD per barrelCrude oil price in United States
- Software and IT Services · 5 records36.5%Business AI adoption in United States
- Chess · 5 records12,485FIDE rated chess players in United States
- Chess · 5 records115Chess grandmasters and titled players in United States
- Electricity and Gas Utilities · 5 records176TWhElectricity consumption in United States
- Chemicals · 5 records9 billionpoundsChemical production in United States
- Electricity and Gas Utilities · 5 records23%LNG exports in United States
- Semiconductors · 4 records425 billionUSDSemiconductor sales in United States
- Electric Vehicles · 4 records1.6 millionElectric car sales in United States
- Electricity and Gas Utilities · 4 records2.1%Electricity demand in United States
- Oil and Gas · 4 records20.6 millionbarrels per dayOil demand in United States
- Software and IT Services · 4 records55%Data center capacity in United States
- Banking · 3 records0.8%Bank deposits in United States
- Pharmaceuticals · 3 records53New medicine launches in United States
- Pharmaceuticals · 3 records210 billiondays of therapyMedicine use in United States
Where United States ranks
- Internet use share by country #29 of 182 · 94.7% · 2024
- Crude steel production by country #3 of 8 · 7.5 million tonnes · May 2026
- New wind power capacity by country #2 of 5 · 6.9 gigawatts · 2025
- Carbon intensity of electricity by country #112 of 191 · 383.8 gCO2e/kWh · 2024
- Life expectancy at birth by country #57 of 210 · 78.9 years · 2024
- Data-only mobile broadband basket price as share of GNI per capita by country #140 of 201 · 0.61% · 2025
- FIDE standard-rated players by country #9 of 200 · 12,596 · October 2026
- FIDE standard-rated female players by country #14 of 194 · 1,005 · October 2026
- Current health expenditure (CHE) as percentage of GDP (%) by country #3 of 192 · 16.7% · 2023
- Domestic general government health expenditure as percentage of GDP (%) by country #7 of 192 · 9.01% · 2023
- Renewable share of electricity generation by country #108 of 192 · 24.1% · 2024
- Current health expenditure (CHE) per capita (US$) by country #1 of 191 · 13,473.2 USD · 2023
- Solar share of electricity generation by country #66 of 191 · 6.92% · 2024
- Fixed broadband basket price as share of GNI per capita by country #165 of 190 · 0.76% · 2025
- Wind power share of electricity mix by country #32 of 189 · 10.3% · 2024
- GDP (current US$) by country #1 of 185 · 30,769,700,000,000 USD · 2025
- GDP per capita, PPP (current international $) by country #10 of 184 · 90,026.5 current international $ · 2025
- FIDE Masters (standard list) by country #4 of 166 · 434 · October 2026
- Mobile-cellular subscriptions per 100 inhabitants by country #93 of 151 · 113.2 per 100 inhabitants · 2024
- School enrollment, primary (% net) by country #70 of 137 · 94.6% · 2017
- FIDE International Masters (standard list) by country #3 of 123 · 189 · October 2026
- School enrollment, secondary (% net) by country #33 of 117 · 92.5% · 2017
- Intentional homicides (per 100,000 people) by country #36 of 104 · 6.51 per 100,000 people · 2022
- FIDE Grandmasters (standard list) by country #2 of 89 · 115 · October 2026
- FIDE Woman Grandmasters (standard list) by country #3 of 63 · 29 · October 2026
- Gini index by country #12 of 57 · 41.8 index · 2023
- Median fixed broadband download speed by country #7 of 25 · 307.2 Mbps · June–August 2026
- Median mobile download speed by country #11 of 25 · 186.6 Mbps · August 2026
- FIDE players rated 2200+ by country #3 of 16 · 1,056 · September 2026
- FIDE rated juniors (born 2008 or later) by country #10 of 12 · 3,140 · September 2026
- Median drug approval time by country #4 of 5 · 322 days · 2025
- New active substance approvals by country #1 of 5 · 50 · 2025
United States by industry
Every measure published for United States, grouped by industry, with its latest value and
trend. Region code US is the same in every industry and in the API.
Retail 46
E-commerce share of total retail sales (not seasonally adjusted) 16.4% −0.3 pp since Q1 2026 Census Bureau 107 records
E-commerce share of total retail sales (seasonally adjusted) 17.1% +0.1 pp since Q1 2026 Census Bureau 107 records
Retail e-commerce sales (quarterly, not seasonally adjusted) 329.5 billion USD +9.4% since Q1 2026 Census Bureau 107 records
Retail e-commerce sales (quarterly, seasonally adjusted) 340.2 billion USD +3.8% since Q1 2026 Census Bureau 107 records
Show 41 more measures
- Halloween celebration participation rate 74%
- Retail-supported employment 55 million
- Containerized import volume, year-on-year growth -3.9%
- Containerized import volume (annual) 25.4 million TEU
- Containerized import volume, year-on-year growth (annual) -0.3%
- Core retail sales, month-over-month change 0.3%
- Core retail sales, year-over-year change 4.72%
- Halloween retail spending 13.1 billion USD
- Retail sales excluding motor vehicles and gasoline, month-over-month change 0.32%
- Retail sales excluding motor vehicles and gasoline, year-over-year change 5.15%
- Total retail sales, month-on-month growth -0.6%
- Average Halloween expenditure per person 115.1 USD
- Building and garden supply stores sales year-over-year change (monthly) -1.2%
- Clothing and accessories stores sales year-over-year change (monthly) 6.55%
- Core retail sales, year-to-date change (year to date) 6.53%
- Electronics and appliance store sales, month-over-month change -0.05%
- Electronics and appliance store sales, year-over-year change 12%
- Furniture and home furnishings stores sales year-over-year change (monthly) 2.71%
- General merchandise stores sales year-over-year change (monthly) 8.3%
- Grocery and beverage stores sales year-over-year change (monthly) 4.52%
- Health and personal care stores sales year-over-year change (monthly) 10.1%
- Marketplace net sales growth 50%
- Price rollbacks count 11,000
- Retail and food services sales growth three-month period year-over-year 6%
- Retail e-commerce sales growth quarter-over-quarter (not seasonally adjusted) 9.4%
- Retail e-commerce sales growth quarter-over-quarter (seasonally adjusted) 3.8%
- Retail e-commerce sales growth year-over-year (not seasonally adjusted) 12.4%
- Retail e-commerce sales growth year-over-year (seasonally adjusted) 12.2%
- Retail industry contribution to GDP (snapshot) 5.3 trillion USD
- Retail sales excluding motor vehicles and gasoline, year-to-date change (year to date) 6.57%
- Revised retail and food services sales growth month-over-month -0.5%
- Rotisserie chicken purse retail price 5.97 USD
- Sporting goods, hobby, music and book stores sales year-over-year change (monthly) -3.01%
- Tariff refunds received 2.9 billion USD
- Total retail sales 763.6 billion USD
- Total retail sales (seasonally adjusted) 1,986.5 billion USD
- Total retail sales growth quarter-over-quarter (seasonally adjusted) 2.9%
- Total retail sales growth year-over-year (not seasonally adjusted) 6.6%
- Total retail sales growth year-over-year (seasonally adjusted) 6.7%
- Total retail sales, year-on-year growth 5%
- Total retail sales, year-on-year growth (quarterly) 6.3%
Healthcare 40
Show 35 more measures
- Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%) 92%
- Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 95%
- Current health expenditure (CHE) as percentage of GDP (%) 16.7%
- Current health expenditure (CHE) per capita (US$) 13,473.2 USD
- Domestic general government health expenditure as percentage of GDP (%) 9.01%
- NCD mortality rate (per 100,000 population) 423.6 per 100,000 people
- Premature NCD mortality probability (ages 30–70, %) 13.7%
- Suicide mortality rate (per 100,000 population) 14.2 per 100,000 people
- Tobacco use prevalence (ages 15+, age-standardized, %) 15.8%
- Tobacco use prevalence: female (ages 15+, age-standardized, %) 11.6%
- Tobacco use prevalence: male (ages 15+, age-standardized, %) 20%
- Net medicine spending growth rate 10.6%
- Annual revenue growth rate of largest patient organizations 5%
- Average annual revenue of patient organizations 12.5 billion USD
- Commercial insurance out-of-pocket cost growth 5%
- Commercial insurance out-of-pocket cost growth (5-year) 37%
- Commercial insurance share of patient out-of-pocket costs 52%
- Drug overdose deaths 67,798
- Drug overdose deaths year-over-year change -12.3%
- Hospitals receiving Medicare IPPS payments 3,000
- Lung cancer screening rate among eligible program members 54%
- Medicare IPPS discharge volume (top 100 DRGs) 7,000,000
- Medicare out-of-pocket cost decline rate 2.2%
- Medicare out-of-pocket cost increase rate versus 2020 23%
- Medicine market average annual growth at net prices (5-year) 9.3%
- Non-retail share of medicine use 16%
- Novel active substance launches, five-year total 270
- Oncology novel active substance (NAS) launches (cumulative) 85
- Patient organizations focused on rare diseases 593
- Patient organizations operating 3,327
- Prescription medicine use growth (5-year) 13%
- Retail pharmacy prescription drug average annual growth (5-year) 2.4%
- Retail share of medicine use 84%
- Rural Health Transformation Program state investment 104 million USD
- Share of patient organizations focused on rare diseases 18%
Economy 10
GDP per capita, PPP (current international $) 90,026.5 current international $ +4.5% since 2024 World Bank 36 records
Electricity and Gas Utilities 62
Show 57 more measures
- Wind power share of electricity mix 10.3%
- Utility-scale battery storage capacity 52 GW
- Coal consumption 452 million short tons
- Electricity demand growth 2.1%
- Electricity generation 4,430 billion kilowatthours
- Liquefied natural gas exports 0.2 billion cubic feet per day
- Planned battery storage capacity additions 14 gigawatts
- Residential electricity price 17.3 cents per kilowatthour
- Solar capacity 151 gigawatts
- Wind capacity 159 gigawatts
- Coal production 528 million short tons
- Coal electricity generation growth -6%
- Commercial electricity sales growth 2.7%
- Electric power sector coal demand growth -6%
- Electricity sales growth 2%
- Industrial electricity sales growth 2.6%
- Natural gas electricity generation growth 1%
- Solar electricity generation growth 18%
- Uranium purchases by nuclear plant operators 46.9 million pounds
- US data centre electricity consumption, LBNL December 2024 vintage 176 TWh
- Utility-scale battery storage capacity additions 20.8 GW
- Utility-scale solar capacity 13.7 GW
- Weighted-average uranium purchase price 58.5 USD per pound
- Wholesale electricity price annual growth 40%
- Wind electricity generation growth 5%
- Average electricity interruption duration per customer 11 hours
- Average electricity interruption frequency per customer 1.5
- Battery storage capacity added 8.3 gigawatts
- Battery storage capacity annual growth rate 70%
- Carbon intensity of electricity generation annual decline rate 2.2%
- Electricity consumption (kilowatthours) 4,211 billion kilowatthours
- Electricity sales 4,135 billion kilowatthours
- Gateway Energy Storage System capacity 250 megawatts
- GE Vernova and Vestas combined wind turbine market share 93%
- Henry Hub natural gas spot price 3.44 USD per million British thermal units
- Liquefied natural gas export growth rate 23%
- Manatee Energy Storage capacity 409 megawatts
- Marketed natural gas production growth rate 4%
- Marketed natural gas production volume change 4.6 billion cubic feet per day
- New wind power capacity installed 6.9 gigawatts
- Planned utility-scale battery storage capacity additions 54 GW
- Pumped storage capacity under development 60 GW
- Relative cost of solar panel manufacturing versus China 3 multiple
- Share of gas-fired power generation 40%
- Share of global wind turbine installations 8%
- Share of planned battery storage capacity in Texas and California 75%
- Solar PV manufacturing capacity growth multiple 3 multiple
- Solar PV share of electricity generation 10%
- Uranium concentrate production 2.1 million pounds
- US data centre electricity consumption: high scenario endpoint 580 TWh
- US data centre electricity consumption: low scenario endpoint 325 TWh
- Utility-scale battery storage capacity (monthly) 7.8 gigawatts
- Utility-scale battery storage capacity addition (snapshot) 1.4 gigawatts
- Wholesale electricity price growth (lower bound) 30%
- Wholesale electricity price growth (upper bound) 40%
- Wind and solar PV capacity additions growth rate 30%
- Wind turbines installed 2,289
Telecommunications 19
Mobile-cellular subscriptions per 100 inhabitants 113.2 per 100 inhabitants +0.7% since 2023 ITU 35 records
Fixed broadband subscriptions per 100 inhabitants 38.9 per 100 inhabitants +2% since 2023 ITU 25 records
Data-only mobile broadband basket price as share of GNI per capita 0.61% 0 pp since 2024 ITU 13 records
Show 14 more measures
- 5G devices connected 259 million
- 5G fixed wireless access subscribers 12 million
- Median fixed broadband download speed 307.2 Mbps
- Median mobile download speed 186.6 Mbps
- Mobile broadband Internet traffic (annual) 132.5 exabytes
- Mobile voice call minutes 2.4 trillion minutes
- New cell towers activated 15 thousand
- Share of global wireless investment 20%
- Share of new home broadband subscribers choosing 5G fixed wireless 99%
- Smartphone price change, 2020-2024 51%
- SMS and MMS messages sent 2.2 trillion
- Wireless connections (all devices) 579 million
- Wireless industry average annual capital investment, 2015-2024 30 billion USD
- Wireless industry capital investment 29 billion USD
Pharmaceuticals 54
Show 49 more measures
- GLP-1, incretin multi-agonist and amylin trial starts 378
- Inflammatory bowel disease drug trial starts 146
- KRAS and RAS inhibitor trial starts 116
- Oncology bispecific antibody trial starts 352
- Radioligand therapy trial starts 127
- Novel drug approvals 46
- Net medicine spending 606 billion USD
- Novel active substance launches 53
- Pharmaceutical and medicine manufacturing total R&D performance 125,986 million USD
- Biosimilar biological product approvals 18
- Cell and gene therapy spending share by geography 62%
- Clinical trial country use share 16%
- Company operating locations 24
- COVID-19 vaccines and therapeutics spending decline 4 billion USD
- First-cycle novel drug approvals 37
- Five-year cumulative medicine use growth 13%
- GIP/GLP-1 agonist spending growth contribution 14 billion USD
- Health sector research and development investment growth rate 7.1%
- Interchangeable biosimilar approvals 9
- Life sciences and patient organization deal value 2.4 billion USD
- Life sciences and patient organization deals 700
- Median drug approval time 322 days
- Medicare patient out-of-pocket medicine cost decline 638 million USD
- Net medicine spending increase 58 billion USD
- New active substance approvals 50
- Novel active substance launches (multi-year total) 270
- Novel antibiotic approvals 3
- Novel drug approvals meeting user fee goal dates 47
- Novel drug approvals using expedited programs 33
- Novel drugs approved first in domestic market 34
- Obesity-approved GIP and GLP-1 agonist medicine spending growth 9.6 billion USD
- Patient out-of-pocket medicine cost increase 6 billion USD
- Patient out-of-pocket medicine costs 110 billion USD
- Pharmaceutical and medicine manufacturing company-funded R&D 114,225 million USD
- Pharmaceutical and medicine manufacturing externally funded R&D 11,761 million USD
- Pharmaceutical and medicine manufacturing R&D funded by domestic companies 2,104 million USD
- Pharmaceutical and medicine manufacturing R&D funded by foreign companies 9 billion USD
- Pharmaceutical and medicine manufacturing R&D funded by other external sources 79 million USD
- Pharmaceutical and medicine manufacturing R&D intensity 17.8%
- Pharmaceutical corporate employment 25,000
- Pharmaceutical manufacturing facility capital investment 750 million USD
- Prescription medicine use 210 billion days of therapy
- Prescription medicine use growth 1.5%
- Projected net medicine spending increase 200 billion USD
- Reference products with biosimilar approvals 8
- Share of first-cycle novel drug approvals 74%
- Share of novel drug approvals meeting user fee goal dates 94%
- Share of novel drug approvals using expedited programs 66%
- Share of novel drugs approved first in domestic market 68%
Software and IT Services 72
U.S. businesses currently using AI (last two weeks) 23.8% +0.6 pp since 6 Sep 2026 Census Bureau 22 records
U.S. businesses: Expected AI Use (Next Six Months) 27.6% +0.3 pp since 6 Sep 2026 Census Bureau 22 records
Show 67 more measures
- Annual job openings for database administrators and architects 7,300 count per year
- Annual job openings for information security analysts 14,100
- Annual job openings in computer and information technology occupations 280,000
- ChatGPT user penetration among US adults 50 and older 28%
- ChatGPT user penetration among US adults under 50 57%
- Cloud infrastructure services spending year-on-year growth rate 37%
- Computer network architects employment 181,800
- Computer programmer employment 110,800
- Computer programmer median hourly wage 48.3 USD per hour
- Computer programmer projected average annual job openings 4,400 count per year
- Computer programmer projected employment change -8,100
- Computer programmer projected employment growth rate -7%
- Computer systems analysts employment 544,400
- Computer systems analysts median annual wage 105,850 USD
- Computer systems analysts projected average annual job openings 32,900
- Computer systems analysts projected employment change 42,900
- Computer systems analysts projected employment growth rate 8%
- Data center capacity growth 2 x
- Employment growth of computer support specialists -3%
- Employment growth of database administrators and architects 4%
- Employment growth of information security analysts 21%
- Employment of computer support specialists 903,100
- Employment of database administrators and architects 144,500
- Employment of information security analysts 192,900
- Finance and Insurance: current business AI use 36.5%
- Hyperscale data centers in future pipeline 437
- Hyperscale owned data center capacity growth 2 x
- Information: current business AI use 43.5%
- Large data center pipeline share 50%
- Manufacturing: current business AI use 23.4%
- Median annual wage for computer and information research scientists 140,300 USD
- Median annual wage for computer and information technology occupations 109,470 USD
- Median annual wage for computer network architects 134,050 USD
- Median annual wage for computer programmers 100,390 USD
- Median annual wage for computer support specialists 62,890 USD
- Median annual wage for database administrators and architects 126,760 USD
- Median annual wage for information security analysts 129,180 USD
- Median annual wage for network and computer systems administrators 99,130 USD
- Median annual wage for software developers, quality assurance analysts, and testers 134,040 USD
- Median annual wage for web developers and digital designers 99,520 USD
- Network and computer systems administrators employment 323,600
- Network and computer systems administrators projected average annual job openings 13,400
- Network and computer systems administrators projected employment change -13,200
- Network and computer systems administrators projected employment growth rate -4%
- Operational hyperscale data centers 580
- Professional, Scientific, and Technical Services: current business AI use 43.3%
- Retail Trade: current business AI use 15.5%
- Software developers median annual wage 135,980 USD
- Software developers, quality assurance analysts, and testers employment 1,905,400
- Software developers, quality assurance analysts, and testers projected average annual job openings 106,100
- Software developers, quality assurance analysts, and testers projected employment change 185,400
- Software developers, quality assurance analysts, and testers projected employment growth rate 10%
- Software quality assurance analysts and testers median annual wage 104,300 USD
- U.S. business AI use: 1-4 Employees 23.6%
- U.S. business AI use: 100-249 Employees 34.5%
- U.S. business AI use: 250+ Employees 38.4%
- US adults aged 18–29 Instagram adoption rate 78%
- US adults aged 18–29 TikTok adoption rate 62%
- US adults aged 65+ Instagram adoption rate 15%
- US adults aged 65+ TikTok adoption rate 10%
7 further measures are in the Software and IT Services page.
Oil and Gas 37
Show 32 more measures
- Natural gas share of electricity generation 40%
- Natural gas spot price 3.53 USD per million Btu
- Oil demand 20.6 million barrels per day
- Retail diesel fuel price 3.66 USD per gallon
- Retail gasoline price 3.1 USD per gallon
- Retail gasoline price (USD) 3.1 USD per gallon
- WTI crude oil spot price 65 USD per barrel
- Marketed natural gas production 118.5 billion cubic feet per day
- Marketed natural gas production growth 4.6 billion cubic feet per day
- Oil and gas industry employment (count) 11 million
- Retail diesel fuel price (USD) 4.4 USD per gallon
- Waterborne petroleum shipments Gulf Coast to West Coast 190,000 barrels per day
- WTI crude oil spot price (year to date) 84 USD per barrel
- Crude oil export capacity 4.9 million barrels per day
- Crude oil production (year to date) 13.7 million barrels per day
- Crude oil production growth 2%
- Crude oil production growth (barrels per day) 0.3 million barrels per day
- Distillate fuel oil inventories 100 million barrels
- Henry Hub natural gas spot price annual change -2%
- Henry Hub natural gas spot price change -0.08 USD per million British thermal units
- Marketed natural gas production (year to date) 121.3 billion cubic feet per day
- Natural gas consumption 2.5 billion cubic feet per day
- Natural gas inventories 3,969 billion cubic feet
- Natural gas inventories deviation from five-year average 5%
- Oil and gas industry employment 11 million jobs
- Permian natural gas production 29.2 billion cubic feet per day
- Refinery utilization rate 97%
- Retail diesel fuel price (USD/gallon) 5.58 USD/gallon
- Shale oil production 7 million barrels per day
- Share of global oil supply growth 90%
- Upstream capital expenditure 150 billion USD/year
- Working natural gas inventories vs year-ago level 1%
Construction 26
Average hourly earnings of production and nonsupervisory employees 38.7 USD +0.9% since June 2026 BLS 8 records
Show 21 more measures
- Number of private industry establishments 295,409
- Total construction spending (seasonally adjusted annual rate) 2,157.6 billion USD
- Workplace fatalities 186
- Building permits 1,374,000
- Private construction spending (seasonally adjusted annual rate) 1,614.2 billion USD
- Private nonresidential construction spending (seasonally adjusted annual rate) 755.2 billion USD
- Private residential construction spending (seasonally adjusted annual rate) 859 billion USD
- Public construction spending (seasonally adjusted annual rate) 543.4 billion USD
- Total construction spending (year-to-date) 1,244.6 billion USD
- Workplace injury and illness rate involving days away from work, job restriction, or transfer 1 cases per 100 full-time workers
- Building permits month-over-month change 5%
- Building permits year-over-year change 3.1%
- Housing completions 1,456,000
- Housing starts 1,432,000
- Private nonresidential construction spending month-over-month change 0.4%
- Private residential construction spending month-over-month change -1.3%
- Public construction spending month-over-month change -0.2%
- Total construction spending month-over-month change -0.5%
- Total construction spending year-over-year change -3.8%
- Total construction spending year-to-date change -3.5%
- Total recordable cases rate of workplace injury and illness 2.2 cases per 100 full-time workers
Education 4
Steel and Basic Metals 23
Show 18 more measures
- Steel import permit applications 2,499,000 net tons
- Steel imports 2,260,147 net tons
- Steel mill shipments growth (monthly) 5.4%
- Crude steel production (net tons) 90 million net tons
- Crude steel production (year to date) 35.6 million tonnes
- Crude steel production growth (annual) 3%
- Crude steel production growth (year to date) 6.8%
- Finished steel import market share (annual) 18%
- Finished steel imports growth -17%
- Finished steel imports growth (monthly) 6.3%
- Steel imports growth (annual) -13%
- Steel imports growth (monthly) 7.4%
- Steel imports month-over-month change -4.3%
- Steel mill shipments 91 million net tons
- Steel mill shipments growth 5%
- Steel shipments month-over-month growth -3.7%
- United States Steel Mill Shipments Growth Year-to-Date 5.3%
- United States Steel Mill Shipments Year-to-Date 55,746,641 net tons
Banking 18
Show 13 more measures
- Number of insured commercial banks and savings institutions 4,238
- Aggregate bank net income quarterly change 9.7 billion USD
- Aggregate bank net income quarterly growth rate 12%
- Community bank net income quarterly growth 8.2%
- Net interest margin 3.32%
- Return on assets 1.37%
- Bank net interest margin 3.39%
- Bank return on assets 1.24%
- Deposit Insurance Fund reserve ratio (snapshot) 1.48%
- Net interest margin quarterly change 1 basis points
- Quarter-over-quarter bank net income growth rate -2%
- Quarter-over-quarter net interest income growth rate 2.2%
- Share of mutual banking organizations with less than 3 billion USD in assets 90%
Airlines and Air Transport 25
Airline passenger enplanements (seasonally adjusted) 80.1 million −3.7% since June 2024 BTS 2 records
Domestic airline passenger enplanements (seasonally adjusted) 69.6 million −3.7% since June 2024 BTS 2 records
International airline passenger enplanements (seasonally adjusted) 10.5 million −5.4% since December 2024 BTS 2 records
Show 20 more measures
- International airline passenger enplanements (unadjusted) 12 million
- Air transportation employment 566,100
- Air transportation employment all-time high 633,600
- Air transportation employment monthly change -0.3%
- Air transportation employment year-over-year change -0.9%
- Airline enplanements month-over-month change, seasonally adjusted (monthly) -0.4%
- Airline enplanements percent change from all-time high (unadjusted) -2.5%
- Airline enplanements percent change from prior year (seasonally adjusted) -1.5%
- Airline enplanements percent change from prior year (unadjusted) -1.4%
- Delta Air Lines net income 3,457 million USD
- Delta Air Lines operating revenue 61.6 billion USD
- Delta Air Lines passenger revenue 50,894 million USD
- Delta Air Lines revenue passenger miles 246,145 million
- Domestic airline enplanements percent change from all-time high (seasonally adjusted) -3.8%
- Domestic airline enplanements percent change from all-time high (unadjusted) -2.2%
- Domestic airline RPK growth -0.6%
- International airline enplanements percent change from all-time high (seasonally adjusted) -4.9%
- International airline enplanements percent change from all-time high (unadjusted) -4.4%
- Preliminary airline passenger enplanement estimate 99.5 million
- Preliminary scheduled-service airline passenger enplanement estimate 88.1 million
Public administration and defence; compulsory social security 1
Intentional homicides (per 100,000 people) 5.76 per 100,000 people −12% since 2022 World Bank 31 records
Hotels and Accommodation 12
Average hourly earnings of production and nonsupervisory employees 21.9 USD −0.3% since June 2026 BLS 4 records
Show 7 more measures
- Production and nonsupervisory employees in the industry 1,756.4 thousand
- Federal per diem standard lodging rate 113 USD
- Federal per diem standard lodging rate increase 3 USD
- Franchised hotels share of total hotels 60%
- Hotel employment multiplier 4.25
- Hotel industry employment 2.2 million
- Total jobs supported by the hotel industry 9.1 million
Information Services 3
Advertising and Market Research 23
Show 18 more measures
- Creator advertising spend (annual) 37 billion USD
- Digital video advertising revenue (annual) 78 billion USD
- Digital video advertising revenue growth (annual) 25.4%
- Digital video advertising share of total digital ad revenue (annual) 26.5%
- Display advertising revenue (annual) 81.6 billion USD
- Display advertising revenue growth (annual) 9.8%
- Display advertising share of total digital ad revenue (annual) 27.7%
- Podcast advertising revenue (annual) 2.9 billion USD
- Podcast advertising revenue growth (annual) 17.6%
- Podcast advertising share of total digital ad revenue (annual) 1%
- Programmatic advertising revenue (annual) 162.4 billion USD
- Programmatic advertising revenue growth (annual) 20.5%
- Search advertising revenue (annual) 114.2 billion USD
- Search advertising revenue growth (annual) 11%
- Search advertising share of total digital ad revenue (annual) 38.8%
- Social media advertising revenue (annual) 117.7 billion USD
- Social media advertising revenue growth (annual) 32.6%
- Social media advertising share of total digital ad revenue (annual) 40%
Semiconductors 14
Show 9 more measures
- Semiconductor industry direct employment 345 thousand
- Semiconductor industry R&D investment 76.8 billion USD
- Semiconductor industry research and development expenditure 70 billion USD
- Semiconductor investment projects announced (multi-year total) 160
- Semiconductor sales by U.S.-headquartered companies 425 billion USD
- Share of foundry sales by customer headquarters 55%
- Share of global semiconductor sales by company headquarters 50.4%
- Share of semiconductor industry revenue from overseas customers 70%
- U.S. share of worldwide semiconductor market 53.4%
Real Estate 14
Housing units authorized by building permits 1,394,000 −2.7% since July 2026 Census Bureau 3 records
Show 9 more measures
- Existing-home sales 3.98 million
- Existing-home sales growth rate (monthly) -2%
- Existing-home sales growth rate (year-to-date) (year to date) 1.6%
- Housing units authorized by building permits growth rate (year-over-year) 3.5%
- Multifamily (5+ units) housing completions 302,000
- Multifamily (5+ units) housing starts 344,000
- Multifamily (5+ units) housing units authorized by building permits 467,000
- Pending Home Sales Index change vs pre-pandemic level -30%
- Single-family housing units authorized by building permits 878,000
Electric Vehicles 17
Show 12 more measures
- Electric truck sales 1,200
- Public charging points 200 thousand
- Public charging points added 35 thousand
- Public fast charging points 50 thousand
- Regional share of global electric car sales 10%
- US Battery Electric Vehicle First Half Sales Share 6%
- US Electric Car Sales Annual Growth 10%
- US Electric Vehicle Registered Fleet Share 2%
- US Electrified Light-Duty Vehicle Market Share 24%
- US Hybrid Electric Vehicle Market Share 16%
- Used electric car market size 400,000
- Zero-emission heavy-duty vehicle sales share forecast 60%
Agriculture and Horticulture 8
Value of specialty crops insured under Federal Crop Insurance Program 21 billion USD +75% since 2011 USDA 4 records
Show 3 more measures
Film and Video 12
Show 7 more measures
- US recorded music streaming revenue 14,877.7 million USD
- US recorded music vinyl revenue 1.4 billion USD
- US TV viewing share: Netflix 8.3%
- US TV viewing share: Paramount Streaming 2.3%
- US TV viewing share: Peacock 1.9%
- US TV viewing share: Streaming 46.7%
- US TV viewing share: The Roku Channel 2.9%
Population 1
Publishing 11
Show 6 more measures
- United States consumer spending on video game content 52.3 billion USD
- United States consumer spending on video game hardware 5.4 billion USD
- United States total consumer spending on video games 60.7 billion USD
- United States video game player population share 67%
- United States video game players 212.3 million
- US video game parent players who play with their children 81%
Chess 8
Show 3 more measures
Chemicals 9
Show 4 more measures
Insurance 4
Broadcasting 2
Fitness and Sports 2
Shipping and Water Transport 1
578 measures. Each name opens the full series; each value opens the record with its source evidence.
Sources
| Document | Publisher | Authority tier | Accessed | Locator | Data points |
|---|---|---|---|---|---|
| Light Duty Electric Drive Vehicles Monthly Sales Updates Data portal | Argonne | T1 Official | 14 Sep 2026 | Latest Monthly Sales Data - Plug-In Vehicle Sales | 3 |
| Exercise or Physical Activity Press release | CDC | T1 Official | 16 Sep 2026 | Exercise or Physical Activity | 2 |
| CDC Launches New Overdose Prevention Data Channel Press release | CDC | T1 Official | 16 Sep 2026 | RELEASE | 2 |
| Twenty-Five Years After 9/11 Press release | CDC | T1 Official | 16 Sep 2026 | WTC Health Program lung cancer screening findings | 1 |
| Data Press release | CMS | T1 Official | 16 Sep 2026 | Medicare provider utilization & payment data: Inpatient Hospital Public Use File (PUF) | 2 |
| Newsroom Articles Press release | CMS | T1 Official | 16 Sep 2026 | Trump Administration Announces $104 Million to Transform Rural Healthcare Across Mississippi Through Cutting-Edge Technology and Expanded Care Closer to Home | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
Showing the 40 documents with the most figures for United States, of 275. Every record page names its own document; the full list is in the CSV download.
Cite this page
Data on this page is published under CC BY 4.0.
Region code US is stable across the API and every hub.
StatOrigin. (2026). United States industry statistics. Retrieved from https://statorigin.org/regions/united-states